Jensen PB - Search Results

1

Transduction potential of human retroviruses in highly proliferating small-cell lung cancer cells as well as non-proliferating hematopoietic stem cells.

Hansen JE, Gram GJ, Nielsen SD, Sørensen A, Jensen PB, Sehested M, Nielsen JO, Rørth M. Hansen JE, et al. Among authors: jensen pb. APMIS. 1997 Sep;105(9):723-9. doi: 10.1111/j.1699-0463.1997.tb05077.x. APMIS. 1997. PMID: 9350217

2

Multidrug resistance and retroviral transduction potential in human small cell lung cancer cell lines.

Theilade MD, Gram GJ, Jensen PB, Cianfriglia M, Rørth M, Hansen JE. Theilade MD, et al. Among authors: jensen pb. APMIS. 1999 Sep;107(9):851-8. doi: 10.1111/j.1699-0463.1999.tb01482.x. APMIS. 1999. PMID: 10519321

3

Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Sorensen M, Sehested M, Jensen PB. Sorensen M, et al. Among authors: jensen pb. Br J Cancer. 1995 Aug;72(2):399-404. doi: 10.1038/bjc.1995.345. Br J Cancer. 1995. PMID: 7640225 Free PMC article.

4

In vitro models for testing of cytostatic agents in small cell lung cancer.

Jensen PB, Sehested M. Jensen PB, et al. Cancer Treat Res. 1995;72:171-91. doi: 10.1007/978-1-4615-2630-8_9. Cancer Treat Res. 1995. PMID: 7702986 Review. No abstract available.

5

Small cell and its stroma: determinant of pan-resistance?

Sehested M, Jensen PB. Sehested M, et al. Among authors: jensen pb. Drug Resist Updat. 1999 Oct;2(5):281-283. doi: 10.1054/drup.1999.0100. Drug Resist Updat. 1999. PMID: 11504501 No abstract available.

6

Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.

Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SP, Sehested M. Brock I, et al. Among authors: jensen pb. Cancer Res. 1995 Feb 1;55(3):459-62. Cancer Res. 1995. PMID: 7834606

7

Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

Jensen PB, Christensen IJ, Sehested M, Hansen HH, Vindeløv L. Jensen PB, et al. Br J Cancer. 1993 Feb;67(2):311-20. doi: 10.1038/bjc.1993.58. Br J Cancer. 1993. PMID: 8094293 Free PMC article.

8

Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.

Sehested M, Jensen PB. Sehested M, et al. Among authors: jensen pb. Biochem Pharmacol. 1996 Apr 12;51(7):879-86. doi: 10.1016/0006-2952(95)02241-4. Biochem Pharmacol. 1996. PMID: 8651936

9

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.

Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. Jensen PB, et al. Br J Cancer. 1997;75(6):869-77. doi: 10.1038/bjc.1997.154. Br J Cancer. 1997. PMID: 9062409 Free PMC article.

10

DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.

Jensen PB, Sehested M. Jensen PB, et al. Biochem Pharmacol. 1997 Oct 1;54(7):755-9. doi: 10.1016/s0006-2952(97)00116-0. Biochem Pharmacol. 1997. PMID: 9353129 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters